Skip to main content

Table 1 Baseline Demographics

From: Vitamin D3 repletion versus placebo as adjunctive treatment of heart failure patient quality of life and hormonal indices: a randomized, double-blind, placebo-controlled trial

 

All Groups

Placebo

Treatment

P-value

Age (years)

67 ± 14

65 ± 16

67 ± 11

0.53

Gender (n, % Female)

13/40 (33%)

6/20 (30%)

7/20 (35%)

0.74

Race (n, % Caucasian)

38/40 (95%)

19/20 (95%)

19/20(95%)

1

BMI (kg/m2−)

29 ± 5

28 ± 5

31 ± 5

0.33

HR (BPM)

72 ± 11

70 ± 10

74 ± 11

0.92

Systolic BP (mmHg)

113 ± 16

117 ± 19

110 ± 14

0.38

Diastolic BP (mmHg)

69 ± 10

71 ± 10

67 ± 10

0.42

EF (%)

28 ± 9

30 ± 11

27 ± 7

0.13

Ischemic (#, %)

25/40 (63%)

14/20 (70%)

11/20 (55%)

0.33

Nonischemic (#, %)

15/40 (37%)

6/20(30%)

9/20 (45%)

0.33

ACE/ARB (#, %)

33/40 (83%)

17/20 (85%)

16/20 (80%)

0.68

Digoxin (#, %)

4/40 (10%)

2/20 (10%)

2/20 (10%)

1

Beta Blocker (#, %)

32/40 (80%)

14/20 (70%)

18/20 (90%)

0.11

Loop Diuretic (#, %)

28/40 (70%)

13/20 (65%)

15/20 (75%)

0.49

Spironolactone and/or Eplerenone

31/40 (78%)

16/20 (80%)

15/20 (75%)

0.70

Statins (#, %)

29/40 (73%)

15/20 (75%)

14/20 (70%)

0.72

  1. Data are expressed as mean ± standard deviation (SD) or number and percentages. Abbreviations: Body Mass Index (BMI), Heart Rate (HR), Blood Pressure (BP), Ejection Fraction (EF) Angiotensin Converting Enzyme Inhibitor (ACE), Angiotensin Receptor Blocker (ARB)